Novel Percutaneous Treatment Strategies for Native Right Ventricular Outflow Tract Dysfunction-Overview of Venus P-Valve

Overview of Venus P-Valve – New Kid on the US Block

Video Transcription

Video Summary

Dr. John Thompson, director of the Pediatric Cath Lab at Johns Hopkins, provided an overview of the venous P valve, which is not yet available in the U.S. The valve is self-expanding and built on a nitinol frame with a porcine pericardial tri-leaflet valve sewn inside. It is different from other valves in that it comes in 10 different sizes and lengths, requiring a different way of sizing and positioning. The valve has been in use since 2013 and has approval for clinical use in the EU, China, and Argentina. Trials are ongoing in other countries, and a pivotal trial approved by the FDA is expected to begin in 2024. Dr. Thompson highlighted the need to assess anatomy and perform balloon sizing before implanting the valve. The valve has shown good performance with no major adverse events and mild to no valve dysfunction. Overall, the venous P valve has been proven reliable and safe for native outflow tract revalving.

Asset Subtitle

John Thomson, MBBS, PhD

Keywords

Pediatric Cath Lab

venous P valve

self-expanding valve

nitinol frame

porcine pericardial tri-leaflet valve